论文部分内容阅读
目的探究血管内皮生长因子(VEGF)及其激酶插入区受体(KDR)、血管内皮生长因子可溶性受体1(sflt-1)与子宫内膜异位症(EMS)发病机制的相关性。方法选择20例EMS患者作为实验组,另选同期实施腹腔镜手术治疗的20例非EMS患者作为对照组,比较两组腹腔积液及血清中VEGF、KDR、sflt-1含量及VEGF活性指数。结果对照组腹腔积液中的sflt-1为(1.12±0.21)ng/ml、VEGF为(10.08±1.53)ng/ml、VEGF活性指数为(12.41±1.38)、KDR为(2.34±0.28)ng/ml,均显著低于实验组的(1.63±0.45)ng/ml、(19.35±2.42)ng/ml、(29.44±2.59)、(3.14±0.35)ng/ml,差异具有统计学意义(P<0.05)。实验组血清中的VEGF、sflt-1、KDR及VEGF活性指数水平均高于对照组,差异具有统计学意义(t=9.980、4.385、10.909、9.404,P<0.05)。结论 VEGF及其KDR、sflt-1与EMS的发病密切相关,临床可将三者作为诊断EMS的重要指标,后期仍需进一步研究不同临床分期的EMS的差异。
Objective To investigate the relationship between the expression of vascular endothelial growth factor (VEGF) and its kinase-inducible kinase (KDR) and soluble vascular endothelial growth factor 1 (sflt-1) and the pathogenesis of endometriosis (EMS) Methods Twenty patients with EMS were selected as the experimental group. Twenty non-EMS patients undergoing laparoscopic surgery at the same period were selected as the control group. The levels of VEGF, KDR, sflt-1 and the activity of VEGF in the two groups were compared. Results The levels of sflt-1 and VEGF in control group were (1.12 ± 0.21) ng / ml and (10.08 ± 1.53) ng / ml respectively, and were 12.41 ± 1.38 and 2.34 ± 0.28 / ml were significantly lower than those in the experimental group (1.63 ± 0.45 ng / ml, (19.35 ± 2.42) ng / ml, (29.44 ± 2.59) and (3.14 ± 0.35) ng / ml, respectively <0.05). The levels of VEGF, sflt-1, KDR and VEGF in experimental group were significantly higher than those in control group (t = 9.980, 4.355, 10.909, 9.404, P <0.05). Conclusions VEGF, KDR and sflt-1 are closely related to the pathogenesis of EMS. Three clinically important indicators for the diagnosis of EMS are still not available. Further studies on the difference of EMS in different clinical stages are still needed in the later stage.